Prosthetic choice in mitral valve replacement for severe chronic ischemic mitral regurgitation: Long-term follow-up
- PMID: 33674062
- DOI: 10.1016/j.jtcvs.2021.01.094
Prosthetic choice in mitral valve replacement for severe chronic ischemic mitral regurgitation: Long-term follow-up
Abstract
Background: Prosthetic choice for mitral valve replacement is generally driven by patient age and patient and surgeon preference, and current guidelines do not discriminate between different etiologies of mitral valve disease. Our objective was to assess and compare short- and long-term outcomes after mitral valve replacement among patients with biological or mechanical prostheses in the setting of severe ischemic mitral regurgitation.
Methods: Between 2000 and 2016, 424 patients underwent mitral valve replacement for severe ischemic mitral regurgitation at our institution, using biological prosthesis in 188 (44%) and mechanical prosthesis in 236 (56%). A 1:1 propensity score match (n = 126 per group) and inverse probability of treatment weighting were used to compare groups. Short-term outcomes included in-hospital mortality and other cardiovascular adverse events. Long-term outcomes included survival and hospital readmission for cardiovascular causes, stroke, and major bleeding.
Results: In-hospital mortality and early postoperative adverse events were similar between groups in the propensity score match and inverse probability of treatment weighting cohorts. Overall long-term survival was similar at 5 and 9 years, but mechanical prosthesis recipients were more frequently readmitted to hospital for cardiovascular causes, including stroke and non-neurological bleeding in propensity score matching and inverse probability of treatment weighting analyses (all P values < .004). Type of prosthesis did not independently influence all-cause mortality (hazard ratio, 1.01; 95% confidence interval, 0.71-1.43; P = .959), but placement of a mechanical prosthesis was associated with increased risk of readmission for cardiovascular events (hazard ratio, 1.65; 95% confidence interval, 1.17-2.32; P = .004) among matched patients.
Conclusions: The type of prosthesis has no influence on long-term survival among patients with severe ischemic mitral regurgitation undergoing mitral valve replacement. There may be an increased risk of neurologic events and serious bleeding associated with mechanical prostheses.
Keywords: ischemic mitral regurgitation; long-term outcomes; mitral valve replacement; prosthesis choice.
Copyright © 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
-
Commentary: Mitral bioprosthesis versus mechanical prosthesis in severe chronic mitral regurgitation: Bioprosthesis wins the duel.J Thorac Cardiovasc Surg. 2023 Feb;165(2):645-646. doi: 10.1016/j.jtcvs.2021.02.082. Epub 2021 Feb 27. J Thorac Cardiovasc Surg. 2023. PMID: 33781594 No abstract available.
-
Commentary: Valve options for ischemic mitral regurgitation in an era of new technologies: ViV(a) la bioprosthetic.J Thorac Cardiovasc Surg. 2023 Feb;165(2):646-647. doi: 10.1016/j.jtcvs.2021.02.076. Epub 2021 Feb 26. J Thorac Cardiovasc Surg. 2023. PMID: 33785217 No abstract available.
-
Commentary: Should all etiologies of mitral regurgitation treated equal?J Thorac Cardiovasc Surg. 2023 Feb;165(2):648-649. doi: 10.1016/j.jtcvs.2021.03.037. Epub 2021 Mar 15. J Thorac Cardiovasc Surg. 2023. PMID: 33838910 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
